⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263513 | 0.78 | — | — | |
| SCHEMBL8169661 | 0.77 | — | — | |
| SCHEMBL14539493 | 0.77 | — | — | |
| SCHEMBL6442999 | 0.77 | — | — | |
| SCHEMBL25180967 | 0.74 | — | — | |
| SCHEMBL4406594 | 0.74 | — | — | |
| SCHEMBL415931 | 0.74 | — | — | |
| SCHEMBL3129296 | 0.74 | — | — | |
| SCHEMBL6629730 | 0.72 | SLC22A6 (0.46) | — | |
| SCHEMBL1226205 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759749-B2 | Therapeutic agent for diabetes | JCR PHARMACEUTICALS CO., LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| EP-3508474-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR Pharmaceuticals Co., Ltd. (JP) | 2019-07-10 | — | — | EP | disclosed |
| US-20190202781-A1 | NOVEL THERAPEUTIC AGENT FOR DIABETES | JCR PHARMACEUTICALS CO., LTD. (JP) | 2019-07-04 | — | — | US | disclosed |
| US-20090042888-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A | 2009-02-12 | — | — | US | disclosed |
| US-7115591-B2 | Pyridazinone compounds as cyclooxygenase [COX] 2 inhibitorsfor gastrointestinal disorders | ABBOTT LABORATORIES (US) | 2006-10-03 | — | — | US | disclosed |
| US-7001895-B2 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | ABBOTT LABORATORIES (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040231558-A1 | Has a clear hue, high light fastness and high moisture resistance | MITSUI CHEMICALS, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| US-20040158064-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2004-08-12 | — | — | US | disclosed |
| EP-1441013-A1 | WATERCOLOR INK | Mitsui Chemicals, Inc. (JP) | 2004-07-28 | — | — | EP | disclosed |
| US-20030225276-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2003-12-04 | — | — | US | disclosed |
| US-20020028938-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-03-07 | — | — | US | disclosed |
| US-20020013318-A1 | Prostaglandin endoperoxide H synthase biosynthesis inhibitors | BLACK LAWRENCE A (US) | 2002-01-31 | — | — | US | disclosed |
| US-6307047-B1 | PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | ABBOTT LABORATORIES | 2001-10-23 | — | — | US | disclosed |
| EP-1124804-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000024719-A1 | PROSTAGLANDIN ENDOPEROXIDE H SYNTHASE BIOSYNTHESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |